Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | CDC25B | P30305 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | ALPL | P05186 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12092823 | 0.90 | MAPT (0.47) | KDM4EMAPTPOLBPDE4DHSD17B10 | |
| SCHEMBL2846088 | 0.86 | HCAR2 (0.59) | KDM4EMAPTPOLBPDE4DHSD17B10 | |
| SCHEMBL2874155 | 0.84 | PDE4D (0.58) | KDM4EMAPTPOLBPDE4DHSD17B10 | |
| SCHEMBL10860621 | 0.84 | KDM4E (0.51) | KDM4EMAPTPOLBPDE4DHSD17B10 | |
| SCHEMBL28835650 | 0.83 | HCAR2 (0.49) | KDM4EMAPTPOLBPDE4DHSD17B10 | |
| SCHEMBL7254411 | 0.82 | MAPT (0.63) | KDM4EMAPTPOLBPDE4DHSD17B10 | |
| SCHEMBL10861249 | 0.82 | PDE4D (0.56) | KDM4EMAPTPOLBPDE4DHSD17B10 | |
| SCHEMBL1456428 | 0.81 | KDM4E (0.49) | KDM4EMAPTPOLBPDE4DHSD17B10 | |
| SCHEMBL19253412 | 0.81 | MAPT (0.55) | KDM4EMAPTPOLBPDE4DHSD17B10 | |
| SCHEMBL2869702 | 0.80 | KDM4E (0.46) | KDM4EMAPTPOLBPDE4DHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025106901-A1 | COMBINATION CANCER THERAPIES WITH A KRAS MODULATOR AND AN RTK-MAPK PATHWAY INHIBITOR | QUANTA THERAPEUTICS, INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| WO-2025106905-A1 | COMBINATION THERAPIES WITH A KRAS MODULATOR AND AN IMMUNOMODULATOR INHIBITOR | QUANTA THERAPEUTICS, INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| EP-4532494-A1 | PYRIMIDINE BASED MODULATORS AND USES THEREOF | Quanta Therapeutics, Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| CN-119604501-A | Pyrimidine-based modulators and uses thereof | 光达治疗公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-117279917-A | Piperazine derivatives and their use in medicine | 成都百裕制药股份有限公司 | 2023-12-22 | — | — | CN | disclosed |
| WO-2023230190-A1 | PYRIMIDINE BASED MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023230190-A1 | PYRIMIDINE BASED MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| WO-2022242750-A1 | PIPERAZINE DERIVATIVE AND USE THEREOF IN MEDICINE | 成都百裕制药股份有限公司 | 2022-11-24 | — | — | WO | disclosed |
| CN-112469412-A | Substituted dihydropyrazolopyrazine carboxamide derivatives | 拜耳公司 | 2021-03-09 | — | — | CN | disclosed |
| US-20140057870-A1 | BICYCLIC TRIAZOLE AND PYRAZOLE LACTAMS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | VANDERBILT UNIVERSITY (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140057870-A1 | BICYCLIC TRIAZOLE AND PYRAZOLE LACTAMS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | VANDERBILT UNIVERSITY (US) | 2014-02-27 | — | — | US | disclosed |
| US-8592422-B2 | Bicyclic triazole and pyrazole lactams as allosteric modulators of mGluR5 receptors | VANDERBILT UNIVERSITY (US) | 2013-11-26 | — | — | US | disclosed |
| EP-2651222-A1 | BICYCLIC TRIAZOLE AND PYRAZOLE LACTAMS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | Vanderbilt University (US) | 2013-10-23 | — | — | EP | disclosed |
| US-20120225844-A1 | BICYCLIC TRIAZOLE AND PYRAZOLE LACTAMS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | JANSSEN-CILAG S.A. (ES) | 2012-09-06 | — | — | US | disclosed |
| US-20120225844-A1 | BICYCLIC TRIAZOLE AND PYRAZOLE LACTAMS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | JANSSEN-CILAG S.A. (ES) | 2012-09-06 | — | — | US | disclosed |
| US-20120225844-A1 | BICYCLIC TRIAZOLE AND PYRAZOLE LACTAMS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | JANSSEN-CILAG S.A. (ES) | 2012-09-06 | — | — | US | disclosed |
| WO-2012083224-A1 | BICYCLIC TRIAZOLE AND PYRAZOLE LACTAMS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | VANDERBILT UNIVERSITY (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012083224-A1 | BICYCLIC TRIAZOLE AND PYRAZOLE LACTAMS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | VANDERBILT UNIVERSITY (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057870-A1 | BICYCLIC TRIAZOLE AND PYRAZOLE LACTAMS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | GRM5, GRIK5, GRIN3A | KDM4E 1748/4885MAPT 669/4885POLB 4658/4885 |
| US-20120225844-A1 | BICYCLIC TRIAZOLE AND PYRAZOLE LACTAMS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | GRM5, GRIK5, GRIN3A | KDM4E 1748/4885MAPT 669/4885POLB 4658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.